News

Researchers from the Nippon Medical School in Tokyo published a report in the journal Respiratory Medicine Case Reports highlighting an individual case study of a patient with pulmonary hypertension associated with idiopathic pulmonary fibrosis that had a good overall improvement after treatment with bosentan. The prevalence…

MediciNova, Inc. a biopharmaceutical company targeting the development of novel small-molecule treatments for conditions with unmet medical needs, recently announced that the U.S. Food and Drug Administration (FDA) approved their protocol for a new clinical trial of MN-001 (under the name tipelukast) as a potential therapeutic for patients with…

ProMetic Life Sciences Inc. reported that their investigational PBI-4050 drug, the firm’s leading anti-fibrotic candidate to address idiopathic pulmonary fibrosis (IPF), was approved to begin clinical trials following CTA clearance by Health Canada. IPF is a devastating, chronic and fatal disease that is characterized by a progressive decline in lung function. It is…

Mutations in telomere genes may cause pulmonary fibrosis, emphysema and impact life expectancy, according to new research results. Telomeres are found at the end of chromosomes, where they act like a protective tip. When cells divide, telomeres shorten. Over the lifespan, with multiple cell division and aging, telomeres get shorter. Eventually telomeres become so short…

The Pulmonary Fibrosis Foundation (PFF), in order to provide top clinical care for those who suffer from Pulmonary Fibrosis (PF), is expanding its PFF Care Center Network (CCN), a patient care concept originally piloted by The University of Chicago’s Pulmonary Clinic. The PFF Care Center…

Cynata Therapeutics Ltd., an Australian stem cell and regenerative medicine company known for its therapeutic stem cell platform technology Cymerus™, has just announced the launch of a study designed to test the platform’s efficacy in administering mesenchymal stem cells (MSCs) in animal models of pulmonary fibrosis (PF). The study will be conducted…

A leader in plant-based biotechnology, iBio, Inc. announced a key new U.S. patent, called “Yersinia pestis Antigens, Vaccine Compositions and Related Methods.” It includes plague antigens that work with the Company’s iBioModulator™ thermostable immunomodulator protein. The technology is directed at providing protection against pneumonic plague, which could be used as a potential form…

Idiopathic pulmonary fibrosis (IPF) is a rare lung condition that mainly causes scarring of the lungs, with symptoms including shortness of breath and persistent dry cough. IPF is a progressive and potentially fatal condition with an unknown cause. At the moment, available treatments are only symptomatic, and much more…

The Department of Veterans Affairs recently completed a randomized controlled-trial aimed to test the efficacy of an interventional pulmonary rehabilitation-structured exercise program for patients with Idiopathic Pulmonary Fibrosis. The incidence and prevalence of Idiopathic Pulmonary Fibrosis (IPF) progressively increases with age, being mostly reflected in older males. Risk factors…

The University of Alabama at Birmingham recently reacted to news of its inclusion into the Pulmonary Fibrosis Foundation Care Center Network, stating that it is an honor in recognition of their commitment towards patients who suffer from pulmonary fibrosis (PF), and that being an official PFFCC will allow them to…